Champions Oncology Inc. (CSBR) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
855 N. WOLFE STREET BALTIMORE, MD 21205 |
| State of Incorp. | DE |
| Fiscal Year End | April 30 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 4/30/2025 | 1/31/2025 MRQ | 4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 3,202 | 2,618 | 10,118 | 9,007 | 4,687 | 8,342 | |||
| Cash and cash equivalent | 3,202 | 2,618 | 10,118 | 9,007 | 4,687 | 8,342 | |||
| Receivables | 15,782 | 9,526 | 8,011 | 9,513 | 6,986 | 4,770 | |||
| Other undisclosed current assets | 713 | 1,495 | 1,328 | 1,144 | 957 | 385 | |||
| Total current assets: | 19,697 | 13,639 | 19,457 | 19,664 | 12,630 | 13,497 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 5,370 | 6,252 | 7,318 | 8,230 | 8,521 | 2,798 | |||
| Property, plant and equipment | 5,040 | 5,721 | 7,186 | 7,134 | 6,090 | 3,993 | |||
| Intangible assets, net (including goodwill) | 335 | 335 | 335 | 335 | 335 | 335 | |||
| Goodwill | 335 | 335 | 335 | 335 | 335 | 335 | |||
| Other noncurrent assets | 185 | 185 | 15 | 15 | 15 | 128 | |||
| Total noncurrent assets: | 10,930 | 12,493 | 14,854 | 15,714 | 14,961 | 7,254 | |||
| TOTAL ASSETS: | 30,627 | 26,132 | 34,311 | 35,378 | 27,591 | 20,751 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 7,360 | 7,960 | 7,604 | 5,282 | 4,125 | 5,642 | |||
| Accounts payable | 5,093 | 5,800 | 5,334 | 2,868 | 1,894 | 3,140 | |||
| Accrued liabilities | 2,267 | 2,160 | 2,270 | 2,414 | 2,231 | 2,502 | |||
| Deferred revenue | 10,922 | 12,094 | 12,776 | 11,071 | 6,256 | 5,815 | |||
| Debt | 154 | 145 | 72 | 628 | |||||
| Other liabilities | 154 | 150 | |||||||
| Other undisclosed current liabilities | 1,280 | 1,337 | 1,208 | 1,054 | 818 | ||||
| Total current liabilities: | 19,870 | 21,541 | 21,733 | 17,479 | 11,199 | 12,085 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 8,412 | 8,783 | 3,170 | ||||||
| Liabilities, other than long-term debt | 5,288 | 6,494 | 7,942 | 391 | 181 | 178 | |||
| Other liabilities | 285 | 401 | 551 | 391 | 181 | 178 | |||
| Operating lease, liability | 5,003 | 6,093 | 7,391 | 8,412 | 8,783 | 3,170 | |||
| Total noncurrent liabilities: | 5,288 | 6,494 | 7,942 | 8,803 | 8,964 | 3,348 | |||
| Total liabilities: | 25,158 | 28,035 | 29,675 | 26,282 | 20,163 | 15,433 | |||
| Equity | |||||||||
| Equity, attributable to parent | 5,469 | (1,903) | 4,636 | 9,096 | 7,428 | 5,318 | |||
| Common stock | 14 | 14 | 14 | 14 | 13 | 13 | |||
| Treasury stock, value | (708) | (708) | (74) | ||||||
| Additional paid in capital | 84,220 | 83,384 | 82,013 | 81,064 | 79,945 | 77,978 | |||
| Accumulated deficit | (78,057) | (84,593) | (77,317) | (71,982) | (72,530) | (72,673) | |||
| Total equity: | 5,469 | (1,903) | 4,636 | 9,096 | 7,428 | 5,318 | |||
| TOTAL LIABILITIES AND EQUITY: | 30,627 | 26,132 | 34,311 | 35,378 | 27,591 | 20,751 | |||
Income Statement (P&L) ($ in thousands)
| 4/30/2025 | 1/31/2025 TTM | 4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 58,591 | 50,155 | 53,870 | 49,109 | 41,040 | 32,123 | ||
| Cost of revenue (Cost of Product and Service Sold) | (28,367) | (29,401) | (29,532) | (23,632) | (21,446) | |||
| Gross profit: | 30,224 | 20,754 | 24,338 | 25,477 | 19,594 | 32,123 | ||
| Operating expenses | (52,302) | (57,511) | (59,126) | (48,502) | (40,674) | (33,926) | ||
| Other undisclosed operating income | 28,367 | 29,401 | 29,532 | 23,632 | 21,446 | |||
| Operating income (loss): | 6,289 | (7,356) | (5,256) | 607 | 366 | (1,803) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | 112 | 48 | (11) | (24) | 71 | (42) | ||
| Interest and debt expense | (8) | (15) | ||||||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (15) | |||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | 6,378 | (7,323) | (5,267) | 583 | 437 | (1,845) | ||
| Other undisclosed income from continuing operations before income taxes | 23 | 15 | ||||||
| Income (loss) from continuing operations before income taxes: | 6,401 | (7,308) | (5,267) | 583 | 437 | (1,845) | ||
| Income tax expense (benefit) | 26 | 32 | (68) | (35) | (75) | (130) | ||
| Income (loss) from continuing operations: | 6,427 | (7,276) | (5,335) | 548 | 362 | (1,975) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | 548 | 362 | (1,975) | |
| Net income (loss) available to common stockholders, diluted: | 6,427 | (7,276) | (5,335) | 548 | 362 | (1,975) | ||
Comprehensive Income ($ in thousands)
| 4/30/2025 | 1/31/2025 TTM | 4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 6,427 | (7,276) | (5,335) | 548 | 362 | (1,975) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 6,427 | (7,276) | (5,335) | 548 | 362 | (1,975) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.